Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 3/20 | 0.57 |
| ▸ | EHMT2 | Q96KQ7 | 3/20 | 0.43 |
| ▸ | PDE4A | P27815 | 3/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.39 |
| ▸ | KLK14 | Q9P0G3 | 1/20 | 0.39 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | KRAS | P01116 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 3/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | PGK1 | P00558 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | FLT4 | P35916 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27041258 | 0.83 | ENPP1 (0.42) | ENPP1EHMT2PDE4APDE4DTNF | |
| SCHEMBL29723105 | 0.82 | PDE4A (0.54) | ENPP1PDE4APDE4DEGFRKRAS | |
| SCHEMBL372259 | 0.82 | PDE4A (0.54) | ENPP1PDE4APDE4DEGFRKRAS | |
| SCHEMBL11556425 | 0.80 | ENPP1 (0.68) | ENPP1EHMT2TNFEGFRKDR | |
| SCHEMBL27057162 | 0.78 | ENPP1 (0.46) | ENPP1EHMT2PDE4APDE4DTNF | |
| SCHEMBL27057125 | 0.78 | ENPP1 (0.49) | ENPP1PDE4APDE4DTNFEGFR | |
| SCHEMBL27882455 | 0.78 | ENPP1 (0.55) | ENPP1PDE4APDE4DTNFL3MBTL1 | |
| SCHEMBL23260607 | 0.76 | ENPP1 (0.59) | ENPP1EHMT2PDE4APDE4DTNF | |
| SCHEMBL14952547 | 0.76 | ENPP1 (0.59) | ENPP1EHMT2PDE4APDE4DTNF | |
| SCHEMBL20509231 | 0.76 | ELANE (0.55) | ENPP1EHMT2EGFRKRASSOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, SOS2, SOST | ENPP1 1234/4885EHMT2 4526/4885PDE4A 3267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.